CWA Asset Management Group’s Pacific Biosciences PACB Stock Holding History

CWA Asset Management Group’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$41.1K	Buy	+10,950	New	+$64.1K	﹤0.01%	528

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

EDRH

Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

CWA Asset Management Group's PACB Position: Q1 2024 in Review

CWA Asset Management Group opened a new position in Pacific Biosciences (PACB) in Q1 2024: 10,950 shares worth $41.1K. The stake represents ﹤0.01% of the portfolio and ranks #528 among its holdings.

268 funds tracked by Wall St. Rank hold PACB as of Q1 2024.

CWA Asset Management Group held 10,950 shares of Pacific Biosciences worth $41.1K as of Q1 2024.
Pacific Biosciences was a new CWA Asset Management Group position in Q1 2024.
Pacific Biosciences made up ﹤0.01% of CWA Asset Management Group's portfolio in Q1 2024, its #528 holding.
268 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2024.

Based on CWA Asset Management Group's 13F filing for Q1 2024, filed 13 May 2024.